Tested Applications
| Positive WB detected in | RAW 264.7 cells, Raji cells |
| Positive IHC detected in | human breast cancer tissue, human prostate cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
22037-1-AP targets Bim in WB, IHC, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag11875 Product name: Recombinant human BIM, BCL2L11 protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 1-198 aa of BC033694 Sequence: MAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSLQTEPQGNPEGNHGGEGDSCPHGSPQGPLAPPASPGPFATRSPLFIFMRRSSLLSRSSSGYFSFDTDRSPAPMSCDKSTQTPSPPCQAFNHYLSAMASMRQAEPADMRPEIWIAQELRRIGDEFNAYYARRVFLNNYQAAEDHPRMVILRLLRYIVRLVWRMH Predict reactive species |
| Full Name | BCL2-like 11 (apoptosis facilitator) |
| Calculated Molecular Weight | 198 aa, 22 kDa |
| Observed Molecular Weight | 23 and 18 kDa |
| GenBank Accession Number | BC033694 |
| Gene Symbol | Bim |
| Gene ID (NCBI) | 10018 |
| RRID | AB_2878978 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | O43521 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for Bim antibody 22037-1-AP | Download protocol |
| WB protocol for Bim antibody 22037-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The BIM/BCL2L11 polyclonal antibody (Cat# 22037-1-AP) has accumulated 34 citations published in journals such as Molecular Cell, Cell Reports, Cell Death Discovery, Advanced Materials, Advanced Science, Biochemical Pharmacology, Frontiers in Pharmacology, Journal of Investigative Dermatology, and Onco Targets & Therapy. Associated research fields include apoptosis, autophagy, multiple cancer types (lung, breast, gastric, cervical, thyroid, glioma), drug resistance mechanisms, neurodegeneration, radiation tissue damage, and intervertebral disc degeneration.
| Species | Application | Title |
|---|---|---|
Adv Mater Selective Organ-Targeting Hafnium Oxide Nanoparticles with Multienzyme-Mimetic Activities Attenuate Radiation-Induced Tissue Damage | ||
Drug Resist Updat TRIM24 promotes T-cell lymphoma development and glucocorticoid resistance via FUS-mediated phase separation of the glucocorticoid receptor | ||
Mol Cell Filamentous GLS1 promotes ROS-induced apoptosis upon glutamine deprivation via insufficient asparagine synthesis. | ||
J Nanobiotechnology Synergistic microenvironment therapy: a dual-function nanogel of supramolecular collagen ll-mimetic matrix and antioxidant MXene for attenuating intervertebral disc degeneration. | ||
Adv Sci (Weinh) EGFR Targeted Liposomal PROTAC Assisted With Epigenetic Regulation as an Efficient Strategy for Osimertinib-Resistant Lung Cancer Therapy | ||
Cell Rep Med FBXO3-mediated DUSP9 ubiquitination promotes leukemia stem cell maintenance and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. |









